If you can't read please download the document
Upload
andrew-ferguson
View
5.053
Download
5
Embed Size (px)
DESCRIPTION
Overview of candidiasis, antifungal pharmacology and the role of echinocandins
Citation preview
2. Overview
3. EPIDEMIOLOGY 4. Clinically relevant fungi/molds Normal flora: Candida spp . Ubiquitous: Aspergillus spp. Cryptococcus spp. Mucor spp. Endemic geographical: Blastomyces spp. Coccidioides spp. Histoplasma spp . Emerging: Scedesporium spp. Fusarium spp. Trichosporin spp. 5. Epidemiology of Candida BSI Wisplinghoff Het al.Nosocomial bloodstream infection in US hospitals. Analysis of 24,179 cases From a prospective nationwide surveillance study. Clin Infect Dis 2004; 39: 309-317.
6. Candida species distribution Author Year N albicans glabrata parapsilosis tropicalis krusei Pfalleret al 2001-04 > 5000 51-60% 10% 12% 9% 5% Guineaet al 1984-2006 307 43.9% 6.2% 39.7% 5.5% 1.6% Mora-Duarteet al 1997-01 224 35 - 54% 9.2-12.8% 18.3-19.8% 12.8-19.8% 0.9-4% Kuseet al 2003-04 392 43 - 44% 8-11% 13-16% 23-26% 3-4% Reboliet al 2003-04 245 59 - 64% 16-25% 10-14% 9-12% n/a Kullberget al 1998-03 370 43 - 51% 15-17% 16-18% 13-21% 1-2% Gareyet al 2002-05 230 56% 17% 11% 7% 3% Parkinset al 1999-04 207 52% 22% 6% 6% 5% Playfordet al 2001-04 183 62% 17.9% 7.8% 5.6% 3.9% Azole S-DD Increased MIC to echinocandin ? clinical significance Azole R 7. Candida Spp. In-vitro Sensitivity S = sensitive I = Intermediate R = Resistant S-DD = Sensitive Dose-dependent Species Fluconazole Itraconazole Posaconazole Voriconazole Ampho B Echinocandins C. albicans S S S S S S C. tropicalis S S S S S S C. parapsilosis S S S S S S (to I?) C. dubliniensis S to S-DD S S S S S C. glabrata S-DD to R S-DD to R S to I S to I S to I S C. krusei R S-DD to R S to I S to I S to I S C. lusitaniae S S S S S to R S 8. Independent risk factors for Candida BSI Schelenz S. Management of candidiasis in the intensive care unit. J Antimicrob Chemother 2008; 61 Suppl 1: i31-i34. Blumberg HMet al . Risk factors for candidal bloodstream infections in surgical intensive care unit patients: the NEMIS prospective multicenter study. Clin Infect Dis 2001; 33: 177-86. Independent Variable Relative risk Odds ratio Abdominal surgery 7.3 Triple lumen CVC 5.4 Acute renal failure 4.2 Parenteral nutrition 3.6 Multiple antibiotics 12.5 Candida elsewhere 10.4 ICU > 7 days 9.8 9. Therapeutic Options Ampho B Deoxycholate Liposomal Ampho B (Ambisome) Ampho B Colloidal Dispersion (ABCD) Ampho B Lipid Complex (ABLC) Itraconazole,Fluconazole, Voriconazole Posaconazole, Ravuconazole Caspofungin , Micafungin,Anidulafungin Flucytosine Polyenes Azoles Echinocandins Antimetabolite 10. Hidden Costs of Therapy Drug Acquisition Costs Adverse Effect Costs Therapy Failure Costs Total Therapy Associated Costs 11. ANTIFUNGAL DRUG TARGETS 12. Fungal Cell Wall Targets Fungal cell Mannoproteins -(1,6)-glucan -(1,3)-glucan Chitin Phospholipid bilayer of cell membrane Cell membrane and cell wall Ergosterol -(1,3)-glucan synthase Squalene DNA/RNA Synthesis Ergosterol Synthesis Pathway 13. Cell membrane Ergosterol Azole Squalene Ergosterol Synthesis Pathway Toxic sterols Accumulation of toxic sterols in cell membrane Inhibition of 14- -demethylase Azoles 14. Cell membrane Ergosterol Amphotericin B Binding to ergosterol, Intercalation of cell membrane K + Na + Ca ++ Ca ++ Na + K + Leakage of intracellular cations and proteins Polyenes 15. (1,3) glucan synthase glucan synthase inhibitor Inhibition of (1,3) glucan synthase Depletion of (1,3) glucansin cell wall Echinocandins Mannoproteins (1,6)-glucan (1,3)-glucan Chitin Phospholipid bilayer of cell membrane 16. Cytosine permease Cytosine deaminase Phosphorylation Inhibition of thymidylate synthase FdUMP Conversion to deoxynucleosides Inhibition of DNA synthesis Inhibition of Protein Synthesis FdUMP FUTP Substitution for uracil 5-FC, 5-fluorocytosine; 5-FU, 5-fluorouracil; FdUMP, 5-fluorodeoxyuridine; FUMP, 5-fluorouridine monophosphate; FUDP,5-fluorouridine diphosphate; FUTP, 5-fluorouridine triphosphate; dUMP, deoxyuridine monophosphate; dTMP, deoxythymidine monophosphate Flucytosine 5-FC 5-FC 5-FU dUMP dTMP 5-FC 17. Fungal Cell Wall Targets Fungal cell Mannoproteins -(1,6)-glucan -(1,3)-glucan Chitin Phospholipid bilayer of cell membrane Cell membrane and cell wall Ergosterol -(1,3)-glucan synthase Squalene DNA/RNA Synthesis AZOLES POLYENES ECHINOCANDINS FLUCYTOSINE Ergosterol Synthesis Pathway 18. ANTIFUNGAL DRUG RESISTANCE 19. Amphotericin B Resistance
20. Azole Resistance
21. Echinocandin Resistance
22. ADVERSE-EFFECTS & INTERACTIONS 23. Adverse Effects
Product data sheets Girois SBet al.Adverse effects of antifungal therapies in invasive fungal infections: review and meta-analysis. Eur J Clin Microbiol Infect Dis 2005; 24: 119-130. Effect AMB-D L-AMB Fluconazole Voriconazole Caspofungin Fever 34.2% 29.2% 1.4% 5.8% 13-27% Nausea 19.2% 12.2% 2% 5.4% ? Rash 2.9% 2.6% 0 ? ? Bronchospasm 7.2% 2.6% 0 ? ? Nephrotoxicity 33.2%* 14.6%* - 8-21%* 2.7%* Abnormal LFTs 16%* 14%* 2%* 10-18%* 14-18%* Abnormal vision - - - 18.7% - 24. Comparative nephrotoxicity 25. Azoles and the P450 System 26. Enzyme inducers and Azole Levels 3A4 2C19 2D6 2C9 1A2 2E1 2A6 2B6 2C8 Fluconazole (~ 50%) Voriconazole (~50%) Isoniazid Rifampicin Phenytoin Carbamezepine Phenobarbital Ritonovir St. Johns Wort Reduction in AUC/C Max 27. Azole Inhibition of CYP P450 Increased serum concentration of Oral hypoglycemics Warfarin Cyclosporin Cyclophosphamide Tacrolimus Sirolimus Phenytoin Carbamezepine Benzodiazepines Calcium channel blockers Statins Isoniazid Rifabutin Quinidine Protease inhibitors(e.g. ritonavir) Busulfan Vincristine Cyclophosphamide Digoxin Loratidine Opioids e.g. alfentanil Taxels Proton pump inhibitors and others 2C19 polymorphism in 5% caucasians and 20% Asians leads to increased voriconazole levels 28. Itraconazole Interactions Gubbins PO. Drug-drug interactions of antifungal agents and implications for patient care.J Invasive Fungal Infect2007;1(4):14455. 29. Fluconazole Interactions Gubbins PO. Drug-drug interactions of antifungal agents and implications for patient care.J Invasive Fungal Infect2007;1(4):14455. 30. Voriconazole Interactions Gubbins PO. Drug-drug interactions of antifungal agents and implications for patient care.J Invasive Fungal Infect2007;1(4):14455. 31. Echinocandin Interactions
Morris MI. Echinocandins in the management of invasive fungal infections. Part 1. Am J Health-Syst Pharm 2006; 63(18): 1693-1703. 32. CHOOSING A DRUG EVIDENCE 33. Therapy Classification Cultured Candida Colonisation Signs of sepsis ?source Prophylactic Presence of Risk Factors Targeted Prophylactic Targeted Empiric Empiric (No colonisation) Candida Colonisation Targeted Adapted from Grenouillet Fet al.J Invasive Fungal Infect 2007; 1(2): 429. 34. What we know
35. Treatment related mortality risk 1.Retention of CVC 2.Inadequate initial fluconazole dose 3.Therapy delayed > 48 hrs Labelle AJet al . Treatment-related risk factors for hospital mortality in Candida bloodstream infections. Crit Care Med 2008; 36: 2967-2972. Retrospective cohort 245 pts with C-BSI 111 in ICU 36. Therapeutic Problem Areas
37. Diagnostic Methods - Candida Guery BPet al . Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive Care Med 2008 DOI 10.1007/s00134-008-1338-7 Marker Sensitivity Specificity 1->3 D glucan 70% 87.1% Mannans (antigen + antibody) 80 93 C. Albicans germ tube antibody IFA IgG 84.4 94.7 PCR 90.9 100 38. Clinical Efficacy Against IC NB Response isNOT100% !! - ? combined therapy Drug Response % Author Caspofungin 73.4 Mora-Duarteet al Ampho B deoxycholate 61.7 Micafungin 89.6 Ruhnkeet al Liposomal Ampho B 89.5 Anidulafungin 75.6 Reboliet al Fluconazole 60.2 Voriconazole 65 Kullberget al Ampho B deoxycholate/fluconazole 71 Fluconazole 70 Rexet al Ampho B deoxycholate 79 39. Comparative in vivo efficacy 40. Making the choice we need to know
41. Echinocandin vs. Biofilm 0 10 20 30 40 50 60 70 80 90 100 0.5 2 16 FLU AMB CAS % Viability (XTT) Antifungal Conc ( g/mL) Ramage et al.Antimicrob Agent Chemother2002;46:3634 Antifungal Killing vs. Biofilm- EmbeddedCandidaspp. C. parapsilosis has higher MIC to caspo but ? not clinically relevant 42. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 575 potentially relevant articles 552excluded for non-random design 23 for detailed evaluation 2 conference abstracts 10 excluded: 1 RCT of different anidulafungin doses 1 RCT monoclonal antibody to HSP 1 incompatible inclusion criteria 4 duplicate publications 1 RCT preventive therapy ! RCT empirical therapy in neutropenia 1 ongoing no results 15 included in meta-analysis 43. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 All-cause mortality: Fluconazole vs other antifungal 44. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 Clinical treatment failure: Fluconazole vs other antifungal 45. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 Microbiological failure: Fluconazole vs other antifungal 46. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 Adverse event discontinuation: Fluconazole vs other antifungal 47. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 All-cause mortality: Echinocandin vs other antifungal 48. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 Clinical treatment failure: Echinocandin vs other antifungal 49. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 Microbiological failure: Echinocandin vs other antifungal 50. Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 Adverse event discontinuation: Echinocandin vs other antifungal 51.
Treatment of Invasive Candidal Infections: Systematic Review and Meta-analysis Anat Gafter-Gvili, MD; Liat Vidal, MD; Elad Goldberg, MD; Leonard Leibovici, MD; Mical Paul, MD Mayo Clin Proc 2008; 83(9): 1011-1021 Conclusions 52. Candidemia & NOT neutropenic
53. Candidemia - neutropenic
54. CHOOSING A DRUG OPINION 55. When to Treat Pappas PG. The patient with candidemia: treatment choices and algorithms. Current Fungal Infection Reports 2008; 2: 112-119. 56. Ostrosky-Zeichner L, Pappas P. Crit Care Med 2006; 34: 857863 57. Guinea Jet al . Empirical treatment of candidemia in intensive care units: fluconazole or broad-spectrum agents? Medical Mycology 2008 DOI 10.1080/13693780802415556
58. Guery BP et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part II. Treatment. Intensive Care Med 2008 DOI 10.1007/s00134-008-1339-6
59. Ruhnke Met al.New options for treatment of candidemia in critically ill patients. Clin Microbiol Infect 2008; 14 Suppl 4: 46-54
60.
However, in critically ill patients who are hemodynamically unstable and have candidemia, especially when the infection is associated with previous or concurrent exposure to azoles, echinocandins appear to be the drugs of first choice 61. The Consensus
YESwe really do need the echinocandins! 62. 63. 64. Comparison of Caspofungin and Amphotericin B for Invasive Candidiasis Jorge Mora-Duarte, M.D., Robert Betts, M.D., Coleman Rotstein, M.D., Arnaldo Lopes Colombo, M.D., Luis Thompson-Moya, M.D., Juanita Smietana, B.S., Robert Lupinacci, M.S., Carole Sable, M.D., Nicholas Kartsonis, M.D., John Perfect, M.D. and the Caspofungin Invasive Candidiasis Study Group N Engl J Med 2002; 347; 25: 2020-2029
65. Anidulafungin versus Fluconazole for Invasive Candidiasis Annette C. Reboli, M.D., Coleman Rotstein, M.D., Peter G. Pappas, M.D., Stanley W. Chapman, M.D., Daniel H. Kett, M.D., Deepali Kumar, M.D., Robert Betts, M.D., Michele Wible, M.S., Beth P. Goldstein, Ph.D., Jennifer Schranz, M.D., David S. Krause, M.D., Thomas J. Walsh, M.D., for the Anidulafungin Study Group N Engl J Med 2007; 356(24): 2472-2482 Randomized, double-blind, international, multicenter study. Anidulafungin non-inferior to fluconazole in the treatment of invasive candidiasis 66. Caspofungin versus Liposomal Amphotericin B forEmpiricalAntifungal Therapy in Patients with Persistent Fever and Neutropenia Thomas J. Walsh, M.D., Hedy Teppler, M.D., Gerald R. Donowitz, M.D., Johan A. Maertens, M.D., Lindsey R. Baden, M.D., Anna Dmoszynska, M.D., Ph.D., Oliver A. Cornely, M.D., Michael R. Bourque, M.S., Robert J. Lupinacci, M.S., Carole A. Sable, M.D. and Ben E. dePauw, M.D., Ph.D. N Engl J Med 2004; 351; 14: 1391-1402 Multinational, double-blind trial 1095 patients, Caspofungin v liposomal AMB Empirical therapy for persistent fever and neutropenia Caspofungin non-inferior to standard therapy Caspofungin less nephrotoxicity and adverse events 67. Micafungin versus Caspofungin for Treatment of Candidemia and Other Forms of Invasive Candidiasis Peter G. Pappas, Coleman M. F. Rotstein, Robert F. Betts, Marcio Nucci, Deepak Talwar, Jan J. De Waele, Jose A. Vazquez, Bertrand F. Dupont, David L. Horn, Luis Ostrosky-Zeichner, Annette C. Reboli, Byungse Suh, Raghunadharao Digumarti, Chunzhang Wu, Laura L. Kovanda, Leah J. Arnold, and Donald N. BuellClinical Infectious Diseases 2007; 45:88393 International, randomized, double-blind trial in adults with invasive candidiasis Micafungin (100 mg) v micafungin (150 mg) v caspofungin (70 mg then 50 mg daily) Micafungin non-inferior to caspofungin 68. Bibliography
69. Bibliography
70. Bibliography
71. Bibliography